RE:RE:RE:RE:RE:Type C Meeting TimingsJourneytc - thanks for your analysis. Actually the updated data from BRACELET-1 showed a median progression-free survival (mPFS) of 9.5 months in the paclitaxel plus pelareorep cohort vs. 6.3 months in the paclitaxel monotherapy cohort for a hazard ratio of 0.29 as of a March 3, 2023 cut-off date, was very good, which was supported by a 95% Confidence Index (CI) (95% CI: 6.5, NR) with 6.5 months at the lower level and not reached yet (NR) for the higher level, suggesting that the PFS could very well be much higher than the 9.5 months reported as of March 3, 2023.
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-that-show-pelareorep-driving-robust-increases-in-progression-free-survival-and-confirm/